Universal Biosensors 관리

관리 기준 확인 2/4

Universal Biosensors CEO는 John Sharman, Jan2020 에 임명되었습니다 의 임기는 4.83 년입니다. 총 연간 보상은 A$ 883.80K, 58.3% 로 구성됩니다. 58.3% 급여 및 41.7% 보너스(회사 주식 및 옵션 포함). 는 A$ 236.78K 가치에 해당하는 회사 주식의 0.69% 직접 소유합니다. 236.78K. 경영진과 이사회의 평균 재임 기간은 각각 3.8 년과 8.5 년입니다.

주요 정보

John Sharman

최고 경영자

AU$883.8k

총 보상

CEO 급여 비율	58.3%
CEO 임기	4.8yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	8.5yrs

최근 관리 업데이트

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15

CEO 보상 분석

John Sharman 의 보수는 Universal Biosensors 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-AU$12m
Jun 30 2024	n/a	n/a	-AU$12m
Mar 31 2024	n/a	n/a	-AU$6m
Dec 31 2023	AU$884k	AU$515k	-AU$7m
Sep 30 2023	n/a	n/a	-AU$18m
Jun 30 2023	n/a	n/a	-AU$20m
Mar 31 2023	n/a	n/a	-AU$26m
Dec 31 2022	AU$532k	AU$483k	-AU$27m
Sep 30 2022	n/a	n/a	-AU$19m
Jun 30 2022	n/a	n/a	-AU$16m
Mar 31 2022	n/a	n/a	-AU$14m
Dec 31 2021	AU$3m	AU$480k	-AU$11m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	n/a	n/a	-AU$6m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	AU$696k	AU$271k	-AU$8m

보상 대 시장: John 의 총 보상 ($USD 574.90K )은 Australian 시장( $USD 297.98K ).

보상과 수익: 회사가 수익성이 없는 동안 John 의 보상이 증가했습니다.

CEO

John Sharman (58 yo)

4.8yrs

테뉴어

AU$883,796

보상

Mr. John Stewart Sharman, M.App.Fin, CA, BEcon has been the Chief Executive Officer at Universal Biosensors, Inc. since 2020. He served as Non-Executive Director at Cann Group Limited from April 27, 2021 t...

리더십 팀

이름	위치	테뉴어	보상	소유권
John Sharman	Chief Executive Officer	4.8yrs	AU$883.80k	0.69% A$ 236.8k
Salesh Balak	CFO & Company Secretary	18yrs	AU$366.11k	0.13% A$ 44.7k
Nicholas Bliesner	Head of Operations	3.5yrs	데이터 없음	데이터 없음
Luke Cossins	Head of Research & Development	3.8yrs	데이터 없음	데이터 없음
Ann Chew	Head of People Strategy & Culture	2.8yrs	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

경험이 풍부한 관리: UBI 의 관리팀은 경험 ( 3.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Craig Coleman	Non-Executive Director	8.4yrs	AU$86.40k	0.33% A$ 111.6k
David Hoey	Independent Non-Executive Director	8.7yrs	AU$77.60k	0.22% A$ 76.2k
Judith Smith	Independent Non-Executive Director	9.7yrs	AU$85.94k	0.15% A$ 50.9k
Mark Crowther	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
Graham McLean	Independent Non-Executive Chairman	2.7yrs	AU$111.33k	0.36% A$ 124.2k
David Church	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
John Loftus	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
Simon Corrie	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
Steve Kitchen	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
Sam Schulman	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
Davide Matino	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음
Eric Wilkes	Member of the Scientific Advisory Panel	no data	데이터 없음	데이터 없음

8.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 이사회: UBI 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.

Universal Biosensors 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Non-Executive Director recently bought AU$50k worth of stock

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. Announces Chairman Changes

Non-Executive Chairman recently bought AU$54k worth of stock

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023)

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

New minor risk - Share price stability

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Full year 2022 earnings: EPS and revenues miss analyst expectations

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Non-Executive Chairman recently bought AU$54k worth of stock

Price target increased to AU$1.15

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Price target increased to AU$1.15

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Non-Executive Chairman recently bought AU$56k worth of stock

Consensus revenue estimates fall by 19%

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Consensus revenue estimates fall by 10%

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Price target increased to AU$1.25

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

New 90-day high: AU$0.54

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic

New 90-day high - AU$0.33

New 90-day high - AU$0.27

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간